$IONS
IONIS PHARMACEUTICALS INC

2024 Q4 Form 10-Q Financial Statement

#000087401524000232 Filed on November 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $133.8M
YoY Change -7.21%
Cost Of Revenue $1.071M
YoY Change -51.12%
Gross Profit $132.7M
YoY Change -6.53%
Gross Profit Margin 99.2%
Selling, General & Admin $61.64M
YoY Change -11.88%
% of Gross Profit 46.43%
Research & Development $220.0M
YoY Change 2.18%
% of Gross Profit 165.73%
Depreciation & Amortization $2.978M
YoY Change -6.94%
% of Gross Profit 2.24%
Operating Expenses $61.64M
YoY Change -11.88%
Operating Profit -$148.7M
YoY Change 3.76%
Interest Expense $4.161M
YoY Change -1.0%
% of Operating Profit
Other Income/Expense, Net $142.0K
YoY Change -94.2%
Pretax Income -$144.1M
YoY Change 2.34%
Income Tax -$3.600M
% Of Pretax Income
Net Earnings -$140.5M
YoY Change -4.7%
Net Earnings / Revenue -104.98%
Basic Earnings Per Share -$0.95
Diluted Earnings Per Share -$0.95
COMMON SHARES
Basic Shares Outstanding 157.9M 146.2M
Diluted Shares Outstanding 148.6M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.829B
YoY Change 8.27%
Cash & Equivalents $334.6M
Short-Term Investments $1.495B
Other Short-Term Assets $184.2M
YoY Change 1.72%
Inventory $28.45M
Prepaid Expenses
Receivables $18.00M
Other Receivables $0.00
Total Short-Term Assets $2.714B
YoY Change 5.0%
LONG-TERM ASSETS
Property, Plant & Equipment $82.50M
YoY Change 16.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $120.3M
YoY Change 15.6%
Total Long-Term Assets $367.2M
YoY Change 5.13%
TOTAL ASSETS
Total Short-Term Assets $2.714B
Total Long-Term Assets $367.2M
Total Assets $3.081B
YoY Change 5.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.052M
YoY Change 61.21%
Accrued Expenses $124.4M
YoY Change 4.56%
Deferred Revenue $76.02M
YoY Change -62.89%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $44.00M
YoY Change 340.0%
Total Short-Term Liabilities $304.6M
YoY Change -24.65%
LONG-TERM LIABILITIES
Long-Term Debt $1.235B
YoY Change -3.46%
Other Long-Term Liabilities $41.74M
YoY Change -14.48%
Total Long-Term Liabilities $41.74M
YoY Change -14.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $304.6M
Total Long-Term Liabilities $41.74M
Total Liabilities $2.419B
YoY Change -7.63%
SHAREHOLDERS EQUITY
Retained Earnings -$2.145B
YoY Change 20.08%
Common Stock $2.832B
YoY Change 31.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $662.5M
YoY Change
Total Liabilities & Shareholders Equity $3.081B
YoY Change 5.01%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$140.5M
YoY Change -4.7%
Depreciation, Depletion And Amortization $2.978M
YoY Change -6.94%
Cash From Operating Activities -$115.0M
YoY Change 5.5%
INVESTING ACTIVITIES
Capital Expenditures $9.056M
YoY Change 331.24%
Acquisitions
YoY Change
Other Investing Activities -$331.7M
YoY Change -568.56%
Cash From Investing Activities -$340.8M
YoY Change -596.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 496.0M
YoY Change -1640.52%
NET CHANGE
Cash From Operating Activities -115.0M
Cash From Investing Activities -340.8M
Cash From Financing Activities 496.0M
Net Change In Cash 40.26M
YoY Change -155.53%
FREE CASH FLOW
Cash From Operating Activities -$115.0M
Capital Expenditures $9.056M
Free Cash Flow -$124.0M
YoY Change 11.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
157813136
CY2023Q4 us-gaap Liabilities
Liabilities
2603386000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Liabilities
Liabilities
2418631000
us-gaap Net Income Loss
NetIncomeLoss
-349548000
us-gaap Net Income Loss
NetIncomeLoss
-357023000
us-gaap Depreciation
Depreciation
7374000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
4666000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-320000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
144340526
us-gaap Increase Decrease In Other Employee Related Liabilities
IncreaseDecreaseInOtherEmployeeRelatedLiabilities
-15397000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19783000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24624000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2514000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-202240000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-187414000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
603358000
us-gaap Increase Decrease In Other Employee Related Liabilities
IncreaseDecreaseInOtherEmployeeRelatedLiabilities
-27169000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
1339284000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
1193724000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
3414000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
33207000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
522174000
ions Maximum Contract Maturity Period Range1
MaximumContractMaturityPeriodRange1
P1Y
CY2024Q3 ions Available For Sale Securities Debt Maturities Within One Year Percentage
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage
0.70
ions Maximum Contract Maturity Period Range2
MaximumContractMaturityPeriodRange2
P2Y
CY2024Q3 ions Available For Sale Securities Debt Maturities After One Through Two Years Percentage
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage
0.23
CY2024Q3 ions Available For Sale Securities Debt Maturities After Two Through Three And One Half Years Percentage
AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage
0.07
CY2024Q3 ions Available For Sale Securities Debt Maturities Total Percentage
AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage
1
CY2024Q3 ions Available For Sale Securities Debt Maturities Within Two Years Percentage
AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage
0.93
ions Maximum Contract Maturity Period Range2
MaximumContractMaturityPeriodRange2
P2Y
CY2024Q3 ions Number Of Privately Held Companies In Which Entity Has Equity Investment
NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment
7
CY2024Q3 ions Debt Securities Available For Sale And Equity Securities Fv Ni Cost
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost
2214500000
CY2024Q3 ions Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Gain
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain
31498000
CY2023Q4 ions Debt Securities Available For Sale And Equity Securities Fv Ni Cost
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost
2002859000
CY2023Q4 ions Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Gain
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain
28715000
CY2023Q4 ions Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Loss
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss
17392000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
451000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
541694000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
762000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-341076000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-345580000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-142534000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
7234000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1877000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1904000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-24219000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-64661000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
75588000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
352060000
us-gaap Interest Paid Net
InterestPaidNet
5714000
CY2023Q4 ions Debt Securities Available For Sale And Equity Securities Fv Ni
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi
2014182000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
213000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
22000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25964000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2145459000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1795911000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
133814000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
157813136
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
144340526
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
158000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
144000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2831942000
ions Research Development And Patent Expense
ResearchDevelopmentAndPatentExpense
643070000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
61638000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
69951000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
179395000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
161608000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
282470000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
287472000
us-gaap Costs And Expenses
CostsAndExpenses
842820000
us-gaap Costs And Expenses
CostsAndExpenses
810749000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-148656000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-143265000
us-gaap Operating Income Loss
OperatingIncomeLoss
-364258000
us-gaap Operating Income Loss
OperatingIncomeLoss
-347607000
CY2024Q3 us-gaap Investment Income Net
InvestmentIncomeNet
26228000
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
23935000
us-gaap Investment Income Net
InvestmentIncomeNet
78112000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-353029000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-331198000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3621000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6602000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3481000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25825000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-140480000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-147410000
us-gaap Net Income Loss
NetIncomeLoss
-349548000
us-gaap Net Income Loss
NetIncomeLoss
-357023000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.95
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.03
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.5
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148593000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148593000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
143052000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
143052000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-140480000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-147410000
us-gaap Net Income Loss
NetIncomeLoss
-349548000
us-gaap Net Income Loss
NetIncomeLoss
-357023000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-153000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129815000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-147410000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
5029000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-153000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
3729000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25964000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-140480000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
10315000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
8680000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
79473000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
33207000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
94558000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
28283000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
895000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
849000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-79850000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
27000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3601000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
8155000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
126000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
122000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
213000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
334605000
us-gaap Income Taxes Paid
IncomeTaxesPaid
2072000
us-gaap Income Taxes Paid
IncomeTaxesPaid
714000
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
21736000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
63000
CY2023Q4 ions Accrued In Licensing Fees Current
AccruedInLicensingFeesCurrent
7454000
CY2024Q3 ions Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
5016000
CY2023Q4 ions Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
4875000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
22059000
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
1492315000
CY2024Q3 ions Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
2885000
CY2024Q3 ions Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
349000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1494851000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31984000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3478000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6435000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1964890000
CY2023Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
35012000
CY2023Q4 ions Equity Securities Fv Ni Accumulated Gross Unrealized Gain
EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain
25237000
CY2023Q4 ions Equity Securities Fv Ni Accumulated Gross Unrealized Loss
EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss
10957000
CY2023Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
49292000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
255
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
334605000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
399266000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
2148671000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
1931935000
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
17928000
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
97778000
CY2024Q3 us-gaap Inventory Net
InventoryNet
28452000
CY2023Q4 us-gaap Inventory Net
InventoryNet
28425000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
184194000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
184449000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2641853000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
26027000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
40558000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
67727000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
304566000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
448090000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
173776000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
241184000
CY2024Q3 ions Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
538102000
CY2023Q4 ions Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
513736000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
168372000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
170875000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-32645000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
7472000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
20396000
ions Interest Expense Related To Sale Of Future Royalties
InterestExpenseRelatedToSaleOfFutureRoyalties
54330000
ions Interest Expense Related To Sale Of Future Royalties
InterestExpenseRelatedToSaleOfFutureRoyalties
50541000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
116814000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
24821000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-19215000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-12462000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-28661000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-142518000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
75751000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-384808000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-340378000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1519227000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1353100000
ions Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
0
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29598000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
124396000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
147894000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
22794000
ions Maximum Contract Maturity Period Range1
MaximumContractMaturityPeriodRange1
P1Y
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
687173000
CY2024Q3 ions Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
3186000
CY2024Q3 ions Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
413000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
689946000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2179488000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6071000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
762000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2184797000
CY2024Q3 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
35012000
CY2024Q3 ions Equity Securities Fv Ni Accumulated Gross Unrealized Gain
EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain
25427000
CY2024Q3 ions Equity Securities Fv Ni Accumulated Gross Unrealized Loss
EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss
11717000
CY2024Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
48722000
CY2024Q3 ions Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Loss
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss
12479000
CY2024Q3 ions Debt Securities Available For Sale And Equity Securities Fv Ni
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi
2233519000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
1316219000
CY2023Q4 ions Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
415000
CY2023Q4 ions Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
5238000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1311396000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
431132000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Assets Current
AssetsCurrent
2713850000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9052000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
124396000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
147894000
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
41000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2151000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
144207000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
478562000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
463142000
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1071000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2191000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6071000
CY2024Q3 ions Research Development And Patent Expense
ResearchDevelopmentAndPatentExpense
219761000
CY2023Q3 ions Research Development And Patent Expense
ResearchDevelopmentAndPatentExpense
215330000
ions Research Development And Patent Expense
ResearchDevelopmentAndPatentExpense
656040000
us-gaap Interest Expense
InterestExpense
12803000
us-gaap Interest Expense
InterestExpense
8102000
CY2024Q3 ions Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties
InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties
18533000
CY2023Q3 ions Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties
InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties
17779000
ions Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties
InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties
54788000
ions Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties
InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties
50948000
CY2023Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
-1943000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-321000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-1753000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
142000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2447000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1029000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13857000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-144101000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-140808000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
143317000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
143317000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146703000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146703000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
10315000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
5029000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8259000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
11421000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
350000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
350000
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
7002000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32490000
us-gaap Net Income Loss
NetIncomeLoss
-357023000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
11421000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
22000
us-gaap Net Income Loss
NetIncomeLoss
-349548000
ions Royalty Payments
RoyaltyPayments
30422000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8680000
ions Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
500000000
ions Payments For Transaction Costs Related To Sale Of Future Royalties
PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties
0
ions Payments For Transaction Costs Related To Sale Of Future Royalties
PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties
10434000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
399266000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
133814000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
144207000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
478562000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
463142000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
110562000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
311000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
151128000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
41735000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
41836000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7385000
us-gaap Investment Income Net
InvestmentIncomeNet
63355000
CY2024Q3 us-gaap Interest Expense
InterestExpense
4161000
CY2023Q3 us-gaap Interest Expense
InterestExpense
4203000
CY2024Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
879000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8259000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
213000
us-gaap Depreciation
Depreciation
7748000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
5016000
us-gaap Share Based Compensation
ShareBasedCompensation
94052000
us-gaap Share Based Compensation
ShareBasedCompensation
79473000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
6653000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
5477000
CY2023Q4 us-gaap Inventory Net
InventoryNet
28425000
CY2024Q3 ions Accrued Clinical Development Expenses
AccruedClinicalDevelopmentExpenses
90239000
CY2023Q4 ions Accrued Clinical Development Expenses
AccruedClinicalDevelopmentExpenses
105967000
CY2024Q3 ions Accrued In Licensing Fees Current
AccruedInLicensingFeesCurrent
7082000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
94052000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
79473000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3500000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25800000
ions Maximum Contract Maturity Period Range3
MaximumContractMaturityPeriodRange3
P3Y6M
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-19125
dei Entity Registrant Name
EntityRegistrantName
Ionis Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0336973
dei Entity Address Address Line1
EntityAddressAddressLine1
2855 Gazelle Court
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92010
dei City Area Code
CityAreaCode
760
dei Local Phone Number
LocalPhoneNumber
931-9200
dei Security12b Title
Security12bTitle
Common Stock, $.001 Par Value
dei Trading Symbol
TradingSymbol
IONS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
157897287
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
82502000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71043000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
164424000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
171896000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
120323000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
105280000
CY2024Q3 us-gaap Assets
Assets
3081099000
CY2023Q4 us-gaap Assets
Assets
2990072000
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
44467000
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
44332000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
76018000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10034000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8831000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-24173000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
662468000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
386686000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3081099000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2990072000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
315460000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
263698000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
662468000
ions Royalty Payments
RoyaltyPayments
27814000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-1429000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
18325000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-2110000
us-gaap Interest Paid Net
InterestPaidNet
952000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Use of Estimates</div> <div><br/> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States, or </span>U.S., that require us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results could differ from our estimates.</div>
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
154000
CY2024Q3 us-gaap Inventory Net
InventoryNet
28452000
ions Maximum Contract Maturity Period Range2
MaximumContractMaturityPeriodRange2
P2Y
CY2024Q3 ions Number Of Publicly Held Companies In Which Entity Has Equity Investment
NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment
3
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
651628000
CY2023Q4 ions Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
3063000
CY2023Q4 ions Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
1197000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
653494000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1967847000
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2215098000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
572887000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
315460000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
386686000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
662468000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
13389000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
575000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
14175000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
487943000
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000874015
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
428301000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
489093000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
489093000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-114000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-14646000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
489093000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
ions Proceeds From Real Estate Transaction
ProceedsFromRealEstateTransaction
0
ions Proceeds From Real Estate Transaction
ProceedsFromRealEstateTransaction
32352000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
276472000
ions Capital And Patent Expenditures Incurred But Not Yet Paid
CapitalAndPatentExpendituresIncurredButNotYetPaid
2240000
ions Capital And Patent Expenditures Incurred But Not Yet Paid
CapitalAndPatentExpendituresIncurredButNotYetPaid
341000
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
11500000
CY2024Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
506000
CY2023Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
506000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
32490000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
25964000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
94558000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
79473000
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
11500000
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
43.5
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
489100000
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
11200000

Files In Submission

Name View Source Status
0000874015-24-000232-index-headers.html Edgar Link pending
0000874015-24-000232-index.html Edgar Link pending
0000874015-24-000232.txt Edgar Link pending
0000874015-24-000232-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10q.htm Edgar Link pending
ions-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ions-20240930_cal.xml Edgar Link unprocessable
ions-20240930_def.xml Edgar Link unprocessable
ions-20240930_lab.xml Edgar Link unprocessable
ions-20240930_pre.xml Edgar Link unprocessable
form10q_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending